Qilu Pharmaceutical has introduced a "first-in-class" antibody pair...

Source: Guanlan Pharmaceutical

On April 16, Qilu Pharmaceutical and Peptron jointly announced that the two parties have reached an exclusive license agreement for the latter's antibody-conjugated drug (ADC) targeting MUC1.

MUC1—an emerging target for cancer immunotherapy

MUC1—an emerging target for cancer immunotherapy

Qilu Pharmaceutical introduced an antibody-conjugated drug targeting MUC1 from Peptron this time.

MUC1 is a highly glycosylated transmembrane protein that plays a vital role in the lubrication and protection of normal epithelial cells.

Studies have found that MUC1 is overexpressed in a variety of human epithelial malignancies, including breast, prostate, ovarian, pancreatic, colon, etc.

According to Peptron's official website, PAb001-ADC is a "first-in-class" antibody conjugate drug targeting MUC1-C.

Picture source: reference [2]

Picture source: reference [2]

According to the press release, the cooperation between Peptron and Qilu Pharmaceutical will accelerate the global development of PAb001-ADC, a potentially differentiated antibody conjugate drug.

It is worth mentioning that MUC1 has become one of the emerging targets in the field of cancer immunotherapy.

At least four "license-in" authorization cooperations have been reached in one year

At least four "license-in" authorization cooperations have been reached in one year

The introduction of innovative drugs from outside has become one of the important ways for Qilu Pharmaceutical to expand its product pipeline.

In February 2021, Qilu Pharmaceuticals obtained the exclusive right to develop and commercialize Cend's drug CEND-1 in Greater China.

In October 2020, Qilu Pharmaceutical obtained the exclusive rights to Quantum Genomics' drug candidate firibastat in China.

In July 2020, Qilu Pharmaceutical obtained the exclusive rights of Sesen Bio's VB4-845 (Vicineum) in Greater China.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

Reference

[1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.

[1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.

[2] Peptron's official website.

[4]Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical.
Retrieved Oct 29, 2020, from https://quantum-genomics.
com/en/press-releases/?ID=ACTUS-0-65617&CLIENT=ACTUS- 0-368

[5] Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China.
Retrieved July 31, 2020, from https://ir.
sesenbio.
com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu

[5] Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China.
Retrieved July 31, 2020, from https://ir.
sesenbio.
com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number